Hariharan Subramanian's Biography

Hariharan Subramanian, Chief Technology Officer, NanoCytomics LLC

Dr. Subramanian is one of the original developers of PWS Nanocytology, the foundational technology platform behind NanoCytomics. He is currently spearheading the company’s clinical implementation of the technology for risk-stratification applications in colon, lung, prostate, esophageal, ovarian and pancreatic cancers. Dr. Subramanian has considerable experience in the areas of biomedical optics, cancer biology and clinical research, with numerous publications appearing in leading peer-reviewed journals. Dr. Subramanian has received multiple research and business challenge awards, and he serves as a technical reviewer for several scientific and medical journals. He received his PhD in biomedical engineering from Northwestern University.

In Vitro Nanocytology Test for Highly Accurate Early Cancer Screening and Prognostication in Primary Care Setting

Monday, 28 September 2015 at 16:00

Add to Calendar ▼2015-09-28 16:00:002015-09-28 17:00:00Europe/LondonIn Vitro Nanocytology Test for Highly Accurate Early Cancer Screening and Prognostication in Primary Care SettingPoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

NanoCytomics, LLC in collaboration with Northwestern University and Boston Medical Center is developing a new in vitro technology platform termed nanocytology for highly sensitive, cost-effective and non-invasive cancer screening and prognostication in a primary care setting. The optical assay measures the nanoscale alterations in chromatin structure as a highly robust and accurate marker of field carcinogenesis in lung, colon, and prostate cancers. A significant application of nanocytology is in cancer screening enabled by the detection of field carcinogenesis via the analysis of the nanoarchitecture of cells obtained from easily accessible surrogate tissue sites with the objective to increase the detection rate of significant pre-neoplastic or neoplastic lesions while reducing overdiagnosis. Examples include the analysis of rectal cells for colon neoplasia and buccal (cheek) cells for lung cancer identification. Data from multi-institutional clinical trials has demonstrated that nanocytology has the potential to become a new platform for cancer screening broadly applicable to a number of organ sites from which cellular specimen can be obtained.

Add to Calendar ▼2015-09-28 00:00:002015-09-30 00:00:00Europe/LondonPoint-of-Care Diagnostics and Global Health World CongressPoint-of-Care Diagnostics and Global Health World Congress in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com

#POCDWC2015 Tweets

Corporate Sponsors